Dechra Pharmaceuticals PLC — Share Issue/Capital Change 2018

Oct 8, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1799D

Dechra Pharmaceuticals PLC

08 October 2018

8 October 2018

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Additional Listing

An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for an increase of 75,000 ordinary shares of 1 pence each in relation to the existing blocklisting (the "Shares") for the Company's Save As You Earn (SAYE) scheme.

These Shares will rank pari passu with the Company's existing shares in issue.  It is expected that admission will become effective on 9 October 2018. 

For further information

For further information, please contact:

Dechra Pharmaceuticals PLC

Melanie Hall, Company Secretary

Telephone number:  +44 (0) 1606 814730

Email: [email protected] 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ALSLLFFSIRLEIIT